Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Trelegy

AstraZeneca AZ

AZ hopes dosing will differentiate its severe asthma therapy

Plans to file benralizumab in EU and US by the end of the year spurred by phase III data

- PMLiVE

Vectura’s Flutiform flunks phase III COPD test

But new AirFluSal data demonstrates superior patient adherence over GSK’s Seretide/Advair

- PMLiVE

Teva gets EU nod for severe asthma drug Cinqaero

Once-monthly dose able to improve asthma control

- PMLiVE

Allergies and asthma

Reframing the conversation from disease burden to prevention and health promotion

- PMLiVE

Boehringer starts to feel impact of Spiriva generics

Asthma and COPD therapy facing increasing competition in ‘crowded’ market category

- PMLiVE

Pfizer buys gene therapy specialist Bamboo

Expands pipeline with Duchenne muscular dystrophy candidate in deal worth $700m

- PMLiVE

GSK and Google launch bioelectronics venture

Will develop electronic implants to treat chronic diseases, including diabetes

- PMLiVE

New drugs breathe life into GSK’s respiratory business

Revlar/Breo and Anoro offset ongoing Seretide decline with new sales growth

Brextinction

Evolution predicts tragic consequences from the UK's choice

- PMLiVE

FCB Health takes home network prize at the Creative Floor Awards

And GSK wins Best Healthcare Company at advertising ceremony

- PMLiVE

Teva’s asthma treatment Cinqaero set for European approval

CHMP backs the antibody therapy for eosinophilic asthma

- PMLiVE

Takeda starts trial of norovirus vaccine

If approved the drug is anticipated to surpass sales of GSK’s Rotarix vaccine

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links